Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IFX-1 (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
Details : Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study met the primary endpoint, where 54% of patients had no visible pustules after a single dose of BI 655130 (spesolimab), compared to 6% receiving placebo at week one. Spesolimab has been granted Breakthrough Therapy Designation in China and USA.
Product Name : Spevigo
Product Type : Antibody
Upfront Cash : Inapplicable
December 23, 2021
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has accepted BLA and granted Priority Review for BI 655130 (spesolimab), a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor for the treatment of generalized pustular psoriasis.
Product Name : Spevigo
Product Type : Antibody
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Spesolimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Product Name : Ifx-1
Product Type : Antibody
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : Ifx-1
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable